



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 401/12, 217/06, A61K 31/47	A1	(11) International Publication Number: WO 99/25709 (43) International Publication Date: 27 May 1999 (27.05.99)
(21) International Application Number: PCT/EP98/07520 (22) International Filing Date: 16 November 1998 (16.11.98) (30) Priority Data: 9724372.9 18 November 1997 (18.11.97) GB (71) Applicant (for all designated States except US): SMITHKLINE BEECHAM P.L.C. [GB/GB]; New Horizons Court, Brentford, Middlesex TW8 9EP (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): COULTON, Steven [GB/GB]; SmithKline Beecham Pharmaceuticals, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB). PORTER, Roderick, Alan [GB/GB]; SmithKline Beecham Pharmaceuticals, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB). THOMPSON, Mervyn [GB/GB]; SmithKline Beecham Pharmaceuticals, New Frontiers Science Park South, Third Avenue, Harlow, Essex CM19 5AW (GB). (74) Agent: WEST, Vivien; SmithKline Beecham, Corporate Intellectual Property, Two New Horizons Court, Brentford, Middlesex TW8 9EP (GB).		(81) Designated States: CA, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: ISOQUINOLINE DERIVATIVES AND THEIR THERAPEUTICAL USE <div style="text-align: center;"> </div> (57) Abstract <p>Carboxamides of general formula (I) are useful for the treatment and/or prophylaxis of anxiety, mania, depression disorders associated with a subarachnoid haemorrhage or neural shock, the effects associated with withdrawal from substances of abuse such as cocaine, nicotine, alcohol and benzodiazepines, disorders treatable and/or preventable with anti-convulsive agents, such as epilepsy including post-traumatic epilepsy, Parkinson's disease, psychosis, migraine, cerebral ischaemia, Alzheimer's disease and other degenerative diseases such as Huntingdon's chorea, schizophrenia, obsessive compulsive disorders (OCD), neurological deficits associated with AIDS, sleep disorders (including circadian rhythm disorders, insomnia & narcolepsy), tics (e.g. Gilles de la Tourette's syndrome), traumatic brain injury, tinnitus, neuralgia, especially trigeminal neuralgia, neuropathic pain, dental pain, cancer pain, inappropriate neuronal activity resulting in neurodysesthesias in diseases such as diabetes, multiple sclerosis (MS) and motor neurone disease, ataxias, muscular rigidity (spasticity), temporomandibular joint dysfunction, panic disorders and/or aggression.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

ISOQUINOLINE DERIVATIVES AND THEIR THERAPEUTICAL USE

This invention relates to novel compounds, to processes for preparing them, and to their use as therapeutic agents.

5


WO96/39382 (Fujisawa) discloses the preparation of N-heterocycl-ureas as 5-HT antagonists, including the compound N-(1-methyl-1H-indol-5-yl)-N'-(1,2,3,4-tetrahydro-7-isoquinoliny)-urea.

- 10 It has now been surprisingly found that heterocycl-N-carboxamide compounds of formula (I) below possess anti-convulsant activity and are therefore believed to be useful in the treatment and/or prevention of anxiety, mania, depression disorders associated with a subarachnoid haemorrhage or neural shock, the effects associated with withdrawal from substances of abuse such as cocaine, nicotine, alcohol and benzodiazepines, disorders
- 15 treatable and/or preventable with anti-convulsive agents, such as epilepsy including post-traumatic epilepsy, Parkinson's disease, psychosis, migraine, cerebral ischaemia, Alzheimer's disease and other degenerative diseases such as Huntingdon's chorea, schizophrenia, obsessive compulsive disorders (OCD), neurological deficits associated with AIDS, sleep disorders (including circadian rhythm disorders, insomnia & narcolepsy),
- 20 tics (e.g. Gilles de la Tourette's syndrome), traumatic brain injury, tinnitus, neuralgia, especially trigeminal neuralgia, neuropathic pain, dental pain, cancer pain, inappropriate neuronal activity resulting in neurodysthesias in diseases such as diabetes, multiple sclerosis (MS) and motor neurone disease, ataxias, muscular rigidity (spasticity), temporomandibular joint dysfunction, panic disorders and/or aggression.

25

Accordingly, the present invention provides a compound of formula (I) or pharmaceutically acceptable salt thereof:

30



(I)

- where P and Q are each independently a bond, methylene or ethylene such the ring
- 35 structure Z is a five or six membered ring,
- R¹ is hydrogen or C₁₋₆ alkyl,

- R^2 is hydrogen or up to four substituents independently selected from halogen, CF_3 , NO_2 , CN , N_3 , C_{1-6} alkylO-, C_{1-6} alkylS-, C_{1-6} alkyl, C_{3-6} cycloalkyl,
- 5 C_{3-6} cycloalkyl- C_{1-4} alkyl-, C_{1-6} alkenyl, C_{1-6} alkynyl, CF_3CO -, CF_3O , C_{1-6} alkylCO-, C_{3-6} cycloalkylCO-, C_{3-6} cycloalkyl- C_{1-4} alkylCO-, phenyl, phenoxy, benzyloxy, benzoyl, phenyl- C_{1-4} alkyl-, or $-NR^4R^5$ where R^4 is hydrogen or C_{1-4} alkyl, and R^5 is hydrogen, C_{1-4} alkyl, $-CHO$, $-CO_2C_{1-4}$ alkyl or $-COC_{1-4}$ alkyl.
- 10 R^3 is hydrogen or up to two C_{1-6} alkyl groups.

- The ring structure Z is a five or six-membered saturated ring, optionally substituted by one or two C_{1-6} alkyl groups, including gem-dialkyl substitution, typically such that compounds of this invention are tetrahydroisoquinoline, tetrahydroquinoline or
- 15 dihydroindole N-carboxamides.

The left hand side tetrahydroisoquinolinyl moiety is typically tetrahydroisoquinolin-5-yl or tetrahydroisoquinolin-7-yl.

- 20 The benzene ring fused to ring structure Z may be substituted by up to four, preferably 2 or 1, non-hydrogen R^2 groups.

- In the formula (I), alkyl groups, including alkyl groups that are part of another moiety, may be straight chain or branched. Aromatic rings, such as the aromatic ring in the
- 25 bicyclic heterocyclic moiety in formula (I) and phenyl groups, including phenyl groups that are part of other moieties, in R^2 may optionally be substituted with one or more independently selected halogen or C_{1-6} alkyl, C_{1-6} alkoxy or C_{1-6} alkylcarbonyl.

- Suitable C_{3-6} cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, and
- 30 cyclohexyl.

Suitable halo substituents include fluoro, chloro, iodo and bromo.

- A suitable group of compounds of formula (I) have substituents selected from:

- 35 R^1 as hydrogen, methyl, ethyl or propyl,
 R^2 as hydrogen, methyl, ethyl, *n*-butyl, phenyl, *iso*-propyl, *t*-butyl, methoxy, ethoxy, *n*-propoxy, *iso*-propoxy, *n*-butoxy, phenoxy, benzyloxy, bromo, chloro, iodo, fluoro, nitro, cyano, acetyl, pivaloyl, *iso*-butyryl, benzoyl, trifluoromethyl, trifluoromethoxy,

trifluoroacetyl, amino, acetylamino, methylthio, *n*-propylsulfonyl, isopropylsulfonyl or dimethylsulfamoyl.

R³ as hydrogen or methyl.

5 Examples of compounds of formula (I) are:

- 2,3-dihydroindole-1-carboxylic acid (2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)amide
3,4-dihydro-1H-isoquinoline-2-carboxylic acid (2-methyl-1,2,3,4-tetrahydro-isoquinolin-7-yl)amide
10 3,4-dihydro-2H-quinoline-1-carboxylic acid (2-methyl-1,2,3,4-tetrahydro-isoquinolin-7-yl)amide
2,3-dihydro-5-methylthio-6-trifluoromethyl-indole-1-carboxylic acid (2-methyl-1,2,3,4-tetrahydroisoquinolin-5-yl)amide
2,3-dihydro-6-methoxyindole-1-carboxylic acid (2-methyl-1,2,3,4-tetrahydro-isoquinolin-7-yl)amide
15 2,3-dihydro-4-methoxyindole-1-carboxylic acid (2-methyl-1,2,3,4-tetrahydro-isoquinolin-7-yl)amide
2,3-dihydro-4,5,6,7-tetrafluoroindole-1-carboxylic acid (2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)amide
20 2,3-dihydro-5-fluoroindole-1-carboxylic acid (2-methyl-1,2,3,4-tetrahydro-isoquinolin-7-yl)amide
2,3-dihydro-5-nitroindole-1-carboxylic acid (2-methyl-1,2,3,4-tetrahydro-isoquinolin-7-yl)amide
2,3-dihydro-6-nitroindole-1-carboxylic acid (2-methyl-1,2,3,4-tetrahydro-isoquinolin-7-yl)amide
25 2,3-dihydro-5-methoxy-6-trifluoromethylindole-1-carboxylic acid (2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)amide
3,3-dimethyl-2,3-dihydroindole-1-carboxylic acid (2-methyl-1,2,3,4-tetrahydro-isoquinolin-7-yl)amide
30 2,3-dimethyl-2,3-dihydroindole-1-carboxylic acid (2-methyl-1,2,3,4-tetrahydro-isoquinolin-7-yl)amide
2,3-dimethyl-2,3-dihydroindole-1-carboxylic acid (2-methyl-1,2,3,4-tetrahydro-isoquinolin-7-yl)amide
3,3-dimethyl--5-fluoro-2,3-dihydroindole-1-carboxylic acid (2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)amide.
35

When synthesised, these compounds may be in salt form, such as the hydrochloride or trifluoroacetate, and such salts also form part of this invention. Such salts may be used in

preparing pharmaceutically acceptable salts. The compounds and their salts may be obtained as solvates, such as hydrates, and these also form part of this invention.

5 The above-listed compounds and pharmaceutically acceptable salts thereof, especially the hydrochloride, and pharmaceutically acceptable solvates, especially hydrates, form a preferred aspect of the present invention.

The administration of such compounds to a mammal may be by way of oral, parenteral, sub-lingual, nasal, rectal or transdermal administration.

10

An amount effective to treat the disorders hereinbefore described depends on the usual factors such as the nature and severity of the disorders being treated and the weight of the mammal. However, a unit dose will normally contain 1 to 1000 mg, suitably 1 to 500 mg, for example an amount in the range of from 2 to 400 mg such as 2, 5, 10, 20, 30, 40, 50,
15 100, 200, 300 and 400 mg of the active compound. Unit doses will normally be administered once or more than once per day, for example 1, 2, 3, 4, 5 or 6 times a day, more usually 1 to 4 times a day, such that the total daily dose is normally in the range, for a 70 kg adult of 1 to 1000 mg, for example 1 to 500 mg, that is in the range of approximately 0.01 to 15 mg/kg/day, more usually 0.1 to 6 mg/kg/day, for example 1 to 6 mg/kg/day.

20

It is greatly preferred that the compound of formula (I) is administered in the form of a unit-dose composition, such as a unit dose oral, including sub-lingual, nasal, rectal, topical or parenteral (especially intravenous) composition.

25 Such compositions are prepared by admixture and are suitably adapted for oral or parenteral administration, and as such may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges, reconstitutible powders, injectable and infusible solutions or suspensions or suppositories. Orally administrable compositions are preferred, in particular shaped oral compositions, since they are more convenient for
30 general use.

Tablets and capsules for oral administration are usually presented in a unit dose, and contain conventional excipients such as binding agents, fillers, diluents, tableting agents, lubricants, disintegrants, colourants, flavourings, and wetting agents. The tablets may be
35 coated according to well known methods in the art.

Suitable fillers for use include cellulose, mannitol, lactose and other similar agents. Suitable disintegrants include starch, polyvinylpyrrolidone and starch derivatives such as

sodium starch glycollate. Suitable lubricants include, for example, magnesium stearate. Suitable pharmaceutically acceptable wetting agents include sodium lauryl sulphate.

These solid oral compositions may be prepared by conventional methods of blending, filling, tableting or the like. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers. Such operations are, of course, conventional in the art.

Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example, almond oil, fractionated coconut oil, oily esters such as esters of glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl *p*-hydroxybenzoate or sorbic acid, and if desired conventional flavouring or colouring agents.

Oral formulations also include conventional sustained release formulations, such as tablets or granules having an enteric coating.

For parenteral administration, fluid unit dose forms are prepared containing the compound and a sterile vehicle. The compound, depending on the vehicle and the concentration, can be either suspended or dissolved. Parenteral solutions are normally prepared by dissolving the compound in a vehicle and filter sterilising before filling into a suitable vial or ampoule and sealing. Advantageously, adjuvants such as a local anaesthetic, preservatives and buffering agents are also dissolved in the vehicle. To enhance the stability, the composition can be frozen after filling into the vial and the water removed under vacuum.

Parenteral suspensions are prepared in substantially the same manner except that the compound is suspended in the vehicle instead of being dissolved and sterilised by exposure to ethylene oxide before suspending in the sterile vehicle. Advantageously, a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound of the invention.

As is common practice, the compositions will usually be accompanied by written or printed directions for use in the medical treatment concerned.

Accordingly, in a further aspect, the present invention provides a pharmaceutical composition for use in the treatment and/or prophylaxis of anxiety, mania, depression disorders associated with a subarachnoid haemorrhage or neural shock, the effects associated with withdrawal from substances of abuse such as cocaine, nicotine, alcohol and benzodiazepines, disorders treatable and/or preventable with anti-convulsive agents, such as epilepsy including post-traumatic epilepsy, Parkinson's disease, psychosis, migraine, cerebral ischaemia, Alzheimer's disease and other degenerative diseases such as Huntingdon's chorea, schizophrenia, obsessive compulsive disorders (OCD), neurological deficits associated with AIDS, sleep disorders (including circadian rhythm disorders, insomnia & narcolepsy), tics (e.g. Gilles de la Tourette's syndrome), traumatic brain injury, tinnitus, neuralgia, especially trigeminal neuralgia, neuropathic pain, dental pain, cancer pain, inappropriate neuronal activity resulting in neurodysthesis in diseases such as diabetes, multiple sclerosis (MS) and motor neurone disease, ataxias, muscular rigidity (spasticity), temporomandibular joint dysfunction, panic disorders and/or aggression which comprises a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier.


The present invention also provides a method of treatment and/or prophylaxis of anxiety, mania, depression disorders associated with a subarachnoid haemorrhage or neural shock, the effects associated with withdrawal from substances of abuse such as cocaine, nicotine, alcohol and benzodiazepines, disorders treatable and/or preventable with anti-convulsive agents, such as epilepsy including post-traumatic epilepsy, Parkinson's disease, psychosis, migraine, cerebral ischaemia, Alzheimer's disease and other degenerative diseases such as Huntingdon's chorea, schizophrenia, obsessive compulsive disorders (OCD), neurological deficits associated with AIDS, sleep disorders (including circadian rhythm disorders, insomnia & narcolepsy), tics (e.g. Gilles de la Tourette's syndrome), traumatic brain injury, tinnitus, neuralgia, especially trigeminal neuralgia, neuropathic pain, dental pain, cancer pain, inappropriate neuronal activity resulting in neurodysthesis in diseases such as diabetes, multiple sclerosis (MS) and motor neurone disease, ataxias, muscular rigidity (spasticity), temporomandibular joint dysfunction, panic disorders and/or aggression comprising administering to the sufferer in need thereof an effective or prophylactic amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof.

In a further aspect the invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, for the manufacture of a medicament for the treatment and/or prophylaxis of anxiety, mania, depression disorders associated with a subarachnoid haemorrhage or neural shock, the effects associated with withdrawal from substances of abuse such as cocaine, nicotine, alcohol and benzodiazepines, disorders

10 treatable and/or preventable with anti-convulsive agents, such as epilepsy including post-traumatic epilepsy, Parkinson's disease, psychosis, migraine, cerebral ischaemia, Alzheimer's disease and other degenerative diseases such as Huntingdon's chorea, schizophrenia, obsessive compulsive disorders (OCD), neurological deficits associated
5 with AIDS, sleep disorders (including circadian rhythm disorders, insomnia & narcolepsy), tics (e.g. Gilles de la Tourette's syndrome), traumatic brain injury, tinnitus, neuralgia, especially trigeminal neuralgia, neuropathic pain, dental pain, cancer pain, inappropriate neuronal activity resulting in neurodysthesias in diseases such as diabetes, multiple sclerosis (MS) and motor neurone disease, ataxias, muscular rigidity (spasticity),
10 temporomandibular joint dysfunction, panic disorders and/or aggression.

In a further aspect the invention provides the use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate, thereof as a therapeutic agent, in particular for
15 the treatment and/or prophylaxis of anxiety, mania, depression disorders associated with a subarachnoid haemorrhage or neural shock, the effects associated with withdrawal from substances of abuse such as cocaine, nicotine, alcohol and benzodiazepines, disorders treatable and/or preventable with anti-convulsive agents, such as epilepsy including post-traumatic epilepsy, Parkinson's disease, psychosis, migraine, cerebral ischaemia, Alzheimer's disease and other degenerative diseases such as Huntingdon's chorea,
20 schizophrenia, obsessive compulsive disorders (OCD), neurological deficits associated with AIDS, sleep disorders (including circadian rhythm disorders, insomnia & narcolepsy), tics (e.g. Gilles de la Tourette's syndrome), traumatic brain injury, tinnitus, neuralgia, especially trigeminal neuralgia, neuropathic pain, dental pain, cancer pain, inappropriate neuronal activity resulting in neurodysthesias in diseases such as diabetes, multiple
25 sclerosis (MS) and motor neurone disease, ataxias, muscular rigidity (spasticity), temporomandibular joint dysfunction, panic disorders and/or aggression.


Another aspect of the invention provides a process for the preparation of compounds of formula (I), which comprises reacting a compound of formula (II)
30



35 where R^{1A} is R^1 as defined for formula (I) or a group convertible to R^1 , with a compound of formula (III)

I

5



- 10 where P, Q and Z are as defined for formula (I), and R^{2A}, R^{3A} are R^2, R^3 as defined for formula (I) or a group or groups convertible to R^2, R^3 and where required converting a R^{1A}, R^{2A} or R^{3A} group to a R^1, R^2 or R^3 group, converting one R^1, R^2 or R^3 group to another R^1, R^2 or R^3 group, converting a salt product to the free base or another salt which is pharmaceutically acceptable, or converting
- 15 a free base product to a pharmaceutically acceptable salt.

Typically the ring structure Z is selected so that compounds of formula (III) are optionally substituted tetrahydroisoquinolines, tetrahydroquinolines or dihydroindoles.


- 20 Conversions of a R^{1A}, R^{2A} or R^{3A} group to a R^1, R^2 or R^3 group typically arise when a protecting group is needed during the above coupling reaction or during the preparation of the reactants by the procedures described below. Interconversion of one R^1, R^2 or R^3 group to another typically arises when one compound of formula (I) is used as the immediate precursor of another compound of formula (I), or when it is easier to introduce a
- 25 more complex or reactive substituent at the end of a synthetic sequence.

Conventional conditions for condensation of isocyanates with amines may be used, for example treatment in an inert solvent such as toluene, DMF or dichloromethane at ambient or elevated temperature.

30

- Compounds of formula (II) may be prepared from the corresponding amines using conventional procedures such as described by I T Forbes *et al*, J. Med. Chem., 1993, 36, 1104, and in Fieser and Fieser, Reagents for Organic Synthesis Vol I. For example an isocyanate may be prepared by stirring a relevant amine with one equivalent of carboxyl
- 35 diimidazole in a suitable solvent such as dichloromethane at room temperature, and then evaporated to dryness *in vacuo*.


The amine precursor of formula (II) may be prepared from the corresponding unsaturated compound of formula (IV)



5

(IV)

by reaction with a compound $R^{1A}Z$ where Z is a leaving group such as halogen, especially iodo, or tosylate to obtain an intermediate of formula (V)




10

(V)

which can be reduced, for example using sodium borohydride, to the compound of formula (II). Alternatively the compound of formula (V) can be hydrogenated, for example using
15 hydrogen at 50psi in a solution of acetic/sulphuric acid with a platinum oxide catalyst.


Another route is from a precursor of formula (VI)



20

(VI)

which can be reacted with $R^{1A}Z$, preferably as a tosylate, to obtain the intermediate of formula (VII)



25

(VII)

which can then be hydrogenated under the conditions previously described.

Compounds of formulae (IV) and (VI) and the reagents used are commercially available, or can be prepared from commercially available materials using conventional procedures
30 described in the literature.

Alternatively, the amine precursor may be prepared directly from the corresponding nitro compound by catalytic hydrogenation. More specifically 7-amino-tetrahydroisoquinolines may be prepared by the procedure of G E Stokker, Tet. Lett. 1996, 37, 5453.

5 When R^{1A} is hydrogen, the amine precursor of the compound of formula (II) can be obtained by direct hydrogenation of the compounds of formula (IV) or (VI), using the reagents already described. The NH may be protected conventionally, for example by making R^{1A} *t*-butoxycarbonyl, prior to formation of the carboxamide, and then
10 deprotected under standard conditions, for example using trifluoroacetic acid/methylene chloride.

Compounds of formula (III) are commercially available or may be prepared by conventional manipulation of substituents on commercially available substituted
15 heterocyclic compounds. Alternatively, compounds of formula (III) may be synthesised by conventional procedures for preparation of tetrahydroisoquinoline, tetrahydroquinoline or dihydroindole compounds with desired substituents *in situ*. For example ring-closing reactions between substituted alkene chlorides and substituted anilines may be used, analogous to those set out in the Descriptions below.

20 The preparation of intermediates and starting materials for the process of this invention is illustrated by the following Descriptions; the preparation of compounds of this invention is illustrated by the following Examples. The utility of compounds of this invention is shown by the Pharmacological Data that follow the Examples.

25

Description 1

N-2-(4-Nitrophenyl)ethyl-trifluoroacetamide

30 A solution of trifluoroacetic anhydride (10.6ml) in dichloromethane (100ml) was added dropwise to a stirred solution of 2,6- lutidine (17.44ml) and 4-nitrophenethylamine hydrochloride (15.2g; 75 mmol) at 0°C. The mixture was stirred at 25°C overnight under argon and then washed with dilute citric acid (x2), brine and dried over Na₂SO₄. The material in the organic phase gave the title compound as a pale yellow solid (19.04g).

35

Description 2

7-Nitro-1,2,3,4-tetrahydro-2-trifluoroacetyl-isoquinoline

The nitro compound D1 (2.26g; 9.15 mmol) and paraformaldehyde (0.45g; 14.4 mmol) in acetic acid (10ml) and conc. H₂SO₄ (15ml) were stirred at 25°C for 20h according to the procedure of G.E. Stokker., Tet. Lett., 1996, 37, 5453. Work up afforded the title compound as a white solid (2.17g).

- 5 ¹H NMR (CDCl₃) δ: 3.10 (2H, m), 3.92 (2H, m), 4.85 + 4.92 (2H, 2xs), 7.38 (1H, t), 8.10 (2H, m); m/z (EI): 274 (M⁺)

Description 3

10 7-Nitro-1,2,3,4-tetrahydroisoquinoline

The trifluoroacetamide D2 (17.22g; 63 mmol) was hydrolysed at room temperature using a solution of potassium carbonate (46.6g) in 10% aqueous methanol (660ml). Work-up with dichloromethane gave the title compound (11g).

15

Description 4

2-Methyl-7-nitro-1,2,3,4-tetrahydroisoquinoline

- 20 The amine D3 (2.08g; 11.7 mmol) was treated with 88% formic acid (3.45ml) and 37% aqueous formaldehyde (5.88ml) at 80°C for 2h according to the procedure of G.M. Carrera and D.S. Garvey, J. Het. Chem., 1992, 29, 847. Basification with 10% sodium hydroxide followed by work-up with ethyl acetate afforded an orange gum (2.3g). Chromatography on Kieselgel 60 in 0-3% methanol - ethyl acetate gave the title compound as an orange solid
25 (1.7g).

m/z (CI): 193 (MH⁺).

Description 5

30

7-Amino-2-methyl-1,2,3,4-tetrahydroisoquinoline

- The 7-nitro compound D4 (0.25g; 1.3 mmol) in methanol (40ml) was hydrogenated over 10% palladium on carbon (100mg) at atmospheric pressure overnight. The catalyst was
35 removed by filtration through a pad of Kieselguhr and evaporation *in vacuo* gave the title compound as a white solid (213mg).

m/z (CI): 163 (MH⁺)

Description 6**2-Methyl-1,2,3,4-tetrahydroisoquinoline-7-isocyanate**

- 5 The amine D5 (245mg, 1.5 mmol) and carbonyldi-imidazole (243mg, 1.5 mmol) in dichloromethane (10ml) were stirred at 25°C for 1h and then evaporated to dryness *in vacuo*.

Description 7

10

5-Amino-2-methylisoquinolinium iodide

- To a solution of 5-aminoisoquinoline (14.4g, 100mmol) in acetone (300ml) was added iodomethane (14.4ml). The solution was briefly stirred and then allowed to stand for 2h.
- 15 The yellow precipitate was then filtered, washed with acetone and dried to afford the title compound as a yellow solid (18.8g).

Description 8**20 5-Amino-2-methyl-1,2,3,4-tetrahydroisoquinoline**

- Sodium borohydride (17.8g, 0.47mol) was added portionwise over 2h to an ice cold solution of 5-amino-2-methylisoquinolinium iodide (18.8g, 65mmol) in methanol (1.5L) and water (60ml). The mixture was then stirred at 25°C for 18h. and concentrated *in vacuo*.
- 25 The residue was extracted into water and dichloromethane. The organic layer was dried (Na₂SO₄) and concentration *in vacuo* gave the title compound (8.87g).

Description 9**30 2-Methyl-1,2,3,4-tetrahydroisoquinoline-5-isocyanate**

The title compound was prepared from amine D8, using a method similar to that of Description 6.

35 Description 10**N-(2-Methyl-2-propenyl)-N-4-fluoroaniline**

A mixture of 4-fluoroaniline (16.7g) and methallyl chloride (11g) was stirred in dimethylformamide (50ml) containing potassium carbonate (16g) for 48 hrs. The reaction mixture was filtered absorbed onto silica gel and column chromatographed petroleum ether then 8% dichloromethane petroleum ether to give the title compound (13.0g)

5 m/z (API⁺): 166 (MH⁺; 100%)

Description 11

N-(2-Methyl-2-propenyl)-N-4-fluoroacetanilide

10

N-(2-methyl-2-propenyl)-N-4-fluoroaniline (8.3g) in dichloromethane was stirred with 4A molecular sieves (1g) 4-dimethylaminopyridine (0.2g) and acetic anhydride (5mls) overnight. the reaction mixture was filtered and washed with water. The organic phase was separated dried, (MgSO₄) and solvent removed at reduced pressure to give the title

15 compound (11.2g)

m/z (API⁺): 208 (MH⁺; 100%)

Description 12

20 5-Fluoro-3,3-gem-dimethylindoline

Aluminium trichloride (1.4g) was suspended in chlorobenzene (8ml) and warmed at 95°C for 1hr. N-(2-methyl-2-propenyl)-N-4-fluoroacetanilide (1.0g) in chlorobenzene (5ml) was added dropwise under argon. The mixture was stirred for 4 hrs, diluted with toluene
25 (20ml) and poured onto ice (80g). The mixture was stirred for 1hr, the organic phase separated, washed with water, dried (MgSO₄) solvent removed at reduced pressure. The residue was column chromatographed (silica gel, dichloromethane/petroleum ether (1:3)) to give the title compound (0.14g).

30 m/z (API⁺): 165 (MH⁺; 100%)

¹H NMR (250MHz, CDCl₃) δ 1.29(6H, s), 3.12(2H, s), 3.59(br. s., 1H), 5.19(1H, dd) and 6.66 - 6.76(2H, m).

Example 1

35

2,3-Dihydroindole-1-carboxylic acid (2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)amide

The residue from Description 6 was dissolved in DMF (10ml), indoline (0.166ml; 1.5 mmol) was added and the mixture was heated at 100°C for 0.5h. The mixture was cooled and partitioned between ethyl acetate and water. The organic phase was washed with water and brine then dried over sodium sulfate and the solvent was removed *in vacuo*.

- 5 Chromatography on SiO₂ in 40 - 100% hexane-ethyl acetate gave the title compound in 77% yield as a colourless gum (353mg).

¹H NMR (250MHz, CDCl₃) δ: 2.42 (3H, s), 2.64 (2H, t, J = 6 Hz), 2.84 (2H, t, J = 6 Hz), 3.15 (2H, t, J = 9 Hz), 3.51 (2H, s), 3.98 (2H, t, J = 9 Hz), 6.57 (1H, s), 6.87 - 7.04 (2H, 10 bm), 7.10 - 7.26 (4H, bm), 7.89 (1H, d, J = 8 Hz); ^{m/z} (API⁺): 308 (MH⁺; 100%).

Example 2

- 15 **3,4-Dihydro-1H-isoquinoline-2-carboxylic acid (2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)amide**

The title compound was prepared in 63% yield from isocyanate D6 and 1,2,3,4-tetrahydroisoquinoline using a method similar to that of Example 1.

- 20 ¹H NMR (250MHz, CDCl₃) δ: 2.43 (3H, s), 2.65 (2H, t, J = 6 Hz), 2.80 - 2.95 (4H, bm), 3.52 (2H, s), 3.70 (2H, t, J = 6 Hz), 4.64 (2H, s), 6.49 (1H, s), 6.96 - 7.24 (7H, bm); ^{m/z} (API⁺): 322 (MH⁺; 100%)

Example 3

25

3,4-Dihydro-2H-quinoline-1-carboxylic acid (2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)amide

- 30 The title compound was prepared in 70% yield from isocyanate D6 and 1,2,3,4-tetrahydroquinoline, using a method similar to that of Example 1.

¹H NMR (250MHz, CDCl₃) δ: 1.98 (2H, dt, J = 6 Hz), 2.44 (3H, s), 2.66 (2H, t, J = 6 Hz), 2.75 - 2.90 (4H, bm), 3.54 (2H, s), 3.82 (2H, t, J = 6 Hz), 6.93 - 7.37 (8H, bm); ^{m/z} (API⁺): 322 (MH⁺; 100%)

35

Example 4

2,3-Dihydro-5-methylthio-6-trifluoromethyl-indole-1-carboxylic acid (2-methyl-1,2,3,4-tetrahydroisoquinolin-5-yl)amide

The title compound was prepared from isocyanate D9 and 2,3-dihydro-5-methylthio-6-trifluoromethyl-indole, using a method similar to that of Example 1.

5 m/z (API⁺): 422 (MH⁺; 100%)

Example 5

10 **2,3-Dihydro-6-methoxyindole-1-carboxylic acid (2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)amide**

The title compound was prepared in 37% yield from isocyanate D6 and 6-methoxy-2,3-dihydroindoline, using a method similar to that of Example 1.

15 ¹H NMR (250MHz, CDCl₃) δ 2.44(s, 3H), 2.67(t, 2H), 2.87(2H, t), 3.14(2H, t), 3.56(2H, s), 3.80(3H, s), 4.05(2H, t), 6.40(s, 1H), 7.02-7.14(m, 3H), 7.19(s, 1H) and 7.61(d, 1H).

m/z (API⁺): 338 (MH⁺; 100%)

20 Example 6

2,3-Dihydro-4-methoxyindole-1-carboxylic acid (2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)amide

25 The title compound was prepared in 46% yield from isocyanate D6 and 4-methoxy-2,3-dihydroindoline, using a method similar to that of Example 1.

¹H NMR (250MHz, d⁶-DMSO) δ 2.35(3H, s), 2.60(2H, br. s), 2.76(2H, br. s.), 3.03(2H, t), 3.46(2H, s), 3.78(3H, s), 4.10(2H, t), 6.57(1H, d), 6.99 - 7.30(4H, m), 7.49(1H, d) and
30 8.37(d, 1H).

m/z (API⁺): 338 (MH⁺; 100%)

35 Example 7

2,3-Dihydro-4,5,6,7-tetrafluoroindole-1-carboxylic acid (2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)amide

The title compound was prepared in 17% yield from isocyanate D6 and 4,5,6,7-tetrafluoro-2,3-dihydroindoline, using a method similar to that of Example 1.

¹H NMR (250MHz, CDCl₃) δ 2.44(3H, s), 2.67(2H, t), 2.88(2H, t), 3.17(2H, t), 3.54(2H, s), 4.24(2H, t), 6.78(1H, d), 7.03 - 7.14 (2H, m) and 7.18(1H, s)

^{m/z} (API⁺): 380 (MH⁺; 100%)

Example 8

2,3-Dihydro-5-fluoroindole-1-carboxylic acid (2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)amide

The title compound was prepared in 10% yield from isocyanate D6 and 5-fluoro-2,3-dihydroindoline, using a method similar to that of Example 1.

¹H NMR (250MHz, CDCl₃) δ 2.45(3H, s), 2.67(2H, t), 2.87(2H, t), 3.22(2H, t), 3.56(2H, s), 4.08(2H, t), 6.30(1H, s), 6.84 - 6.90(2H, m), 7.03 - 7.13 (2H, m), 7.20(1H, s) and 7.88(1H, m)

^{m/z} (API⁺): 326 (MH⁺; 100%)

Example 9

2,3-Dihydro-5-nitroindole-1-carboxylic acid (2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)amide

The title compound was prepared in 43% yield from isocyanate D6 and 5-nitro-2,3-dihydroindoline, using a method similar to that of Example 1.

¹H NMR (250MHz, CDCl₃) δ 2.45(3H, s), 2.68(2H, t), 2.89(2H, t), 3.37(2H, t), 3.57(2H, s), 4.19(2H, t), 6.44(1H, s), 7.06 - 7.15(2H, m), 7.20(1H, s) 8.04(1H, s) and 8.07 - 8.15(2H, m)

^{m/z} (API⁺): 353 (MH⁺; 100%)

Example 10

2,3-Dihydro-6-nitroindole-1-carboxylic acid (2-methyl-1,2,3,4-tetrahydro-

isoquinolin-7-yl)amide

The title compound was prepared in 43% yield from isocyanate D6 and 6-nitro-2,3-dihydroindoline, using a method similar to that of Example 1.

5

¹H NMR (250MHz, CDCl₃) δ 2.45(3H, s), 2.68(2H, t), 2.89(2H, t.), 3.34(2H, t), 3.57(2H, s), 4.17(2H, t), 6.36(1H, s), 7.05 - 7.15(2H, m), 7.26(2H, m) 7.84(1H, dd) and 8.81(1H, d).

^{m/z} (API⁺): 353 (MH⁺; 100%)

10

Example 11**2,3-Dihydro-5-methoxy-6-trifluoromethylindole-1-carboxylic acid (2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)amide**

15

The title compound was prepared in 20% yield from isocyanate D6 and 2,3-Dihydro-5-methoxy-6-trifluoromethylindoline, using a method similar to that of Example 1.

¹H NMR (250MHz, CDCl₃) δ 2.44(3H, s), 2.67(2H, t), 2.87(2H, t.), 3.26(2H, t), 3.56(2H, s), 3.85(3H, s), 4.07(2H, t), 6.27(1H, s), 6.85(1H, s), 7.03 - 7.09(2H, m), 7.19(1H, s) and 8.22(1H, d).

20

^{m/z} (API⁺): 406 (MH⁺; 100%)

25 **Example 12****3,3-Dimethyl-2,3-dihydroindole-1-carboxylic acid (2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)amide**

30 The title compound was prepared in 16% yield from isocyanate D6 and 3,3-dimethyl-2,3-dihydroindoline, using a method similar to that of Example 1.

¹H NMR (250MHz, CDCl₃) δ 1.38(6H, s), 2.45(3H, s), 2.67(2H, t), 2.87(2H, t.), 3.57(2H, s), 3.87(2H, s), 6.42(1H, s), 6.96- 7.26 (6H, m) and 7.87(1H, d).

35

^{m/z} (API⁺): 336 (MH⁺; 100%)

Example 13**2, 3-Dimethyl-2,3-dihydroindole-1-carboxylic acid (2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)amide (3:1 trans:cis)**

5

The title compound was prepared in 55% yield from isocyanate D6 and 2,3-dimethyl-2,3-dihydroindoline (3:1 trans:cis), using a method similar to that of Example 1.

¹H NMR (250MHz, CDCl₃) δ 1.27(3H, d), 1.39(3H, d), 2.45(3H, s), 2.67(2H, br. s.),
10 2.88(3H, br. s.), 3.57(2H, s), 4.07(1H, m), 6.62 (1H, s), 6.99 - 7.25(6H) and 7.66(d, 1H).

m/z (API⁺): 336 (MH⁺; 100%)

Example 14

15

2, 3-Dimethyl-2,3-dihydroindole-1-carboxylic acid (2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)amide (1:2 trans:cis)

The title compound was prepared in 55% yield from isocyanate D6 and 2,3-dimethyl-2,3-dihydroindoline (1:2 trans:cis), using a method similar to that of Example 1.

¹H NMR (250MHz, CDCl₃) δ 1.21(3H, d), 1.32(3H, d), 2.45(3H, s), 2.67(2H, br. s.),
20 2.87(2H, br. s.), 3.57(3H, br. s), 4.57(1H, m), 6.66 (1H, s), 6.99 - 7.25(6H) and 7.58(d, 1H).

25 m/z (API⁺): 336 (MH⁺; 100%)

Example 15**3,3-Dimethyl--5-fluoro-2,3-dihydroindole-1-carboxylic acid (2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)amide**

The title compound was prepared in 30% yield from isocyanate D6 and 3,3-dimethyl--5-fluoro-2,3-dihydroindoline (description 12), using a method similar to that of Example 1.

35 ¹H NMR (250MHz, CDCl₃) δ 1.39(6H, s), 2.45(3H, s), 2.67(2H, t), 2.87(2H, t.), 3.57(2H, s), 3.81(2H, s), 6.29(1H, s), 6.81- 6.91 (2H, m) 7.04 - 7.14(2H, m), 7.22(1H, s) and 7.87(1H, dd).

m/z (API⁺): 3354 (MH⁺; 100%)

PHARMACOLOGICAL DATA

1. Binding Assay Method

- 5 WO 92/22293 (SmithKline Beecham) discloses compounds having anti-convulsant activity, including *inter alia* the compound *trans*-(+)-6-acetyl-4S-(4-fluorobenzoylamino)-3,4-dihydro-2,2-dimethyl-2H-1-benzopyran-3R-ol (hereinafter referred to as Compound A). It has been found that the compounds of WO 92/22293 bind to a novel receptor obtainable from rat forebrain tissue, as described in WO 96/18650 (SmithKline Beecham).
- 10 The affinity of test compounds to the novel receptor site is assessed as follows.

Method

- Whole forebrain tissue is obtained from rats. The tissue is first homogenised in buffer
- 15 (usually 50mM Tris/HCl, pH 7.4). The homogenised tissue is washed by centrifugation and resuspension in the same buffer, then stored at -70°C until used.

- To carry out the radioligand binding assay, aliquots of tissue prepared as above (usually at a concentration of 1-2mg protein/ml) are mixed with aliquots of [3H]-Compound A
- 20 dissolved in buffer. The final concentration of [3H]-Compound A in the mixture is usually 20nM. The mixture is incubated at room temperature for 1 hour. [3H]-Compound A bound to the tissue is then separated from unbound [3H]-Compound A by filtration through Whatman GF/B glass fibre filters. The filters are then washed rapidly with ice-cold buffer. The amount of radioactivity bound to the tissue trapped on the filters is measured by
- 25 addition of liquid scintillation cocktail to the filters followed by counting in a liquid scintillation counter.

- In order to determine the amount of "specific" binding of [3H]-Compound A, parallel assays are carried out as above in which [3H]-Compound A and tissue are incubated
- 30 together in the presence of unlabelled Compound A (usually 3 μ M). The amount of binding of [3H]-Compound A remaining in the presence of this unlabelled compound is defined as "non-specific" binding. This amount is subtracted from the total amount of [3H]-Compound A binding (i.e. that present in the absence of unlabelled compound) to obtain the amount of "specific" binding of [3H]-Compound A to the novel site.
- 35

The affinity of the binding of test compounds to the novel site can be estimated by incubating together [3H]-Compound A and tissue in the presence of a range of concentrations of the compound to be tested. The decrease in the level of specific [3H]-Compound A binding as a result of competition by increasing concentrations of the

compound under test is plotted graphically, and non-linear regression analysis of the resultant curve is used to provide an estimate of compound affinity in terms of pKi value.

Results

- 5 Compounds of this invention were active in this test with pKi values greater than 6. For example, the compound of Example 1 gave a pKi value greater than 8.

2. MEST Test

- 10 The maximal electroshock seizure (MEST) threshold test in rodents is particularly sensitive for detecting potential anticonvulsant properties¹. In this model, anticonvulsant agents elevate the threshold to electrically-induced seizures whilst proconvulsants lower the seizure threshold.

15 Method for mouse model

- Mice (naive male, Charles River, U.K. CD-1 strain, 25 - 30g) are randomly assigned to groups of 10 - 20 and dosed orally or intraperitoneally at a dose volume of 10 ml/kg with various doses of compound (0.3 - 300 mg/kg) or vehicle. Mice are then subjected at 30 or
20 60 min post dose to a single electroshock (0.1 sec, 50Hz, sine wave form) administered via corneal electrodes. The mean current and standard error required to induce a tonic seizure in 50% (CC₅₀) of the mice in a particular treatment group is determined by the 'up and down' method of Dixon and Mood (1948)². Statistical comparisons between vehicle- and drug-treated groups are made using the method of Litchfield and Wilcoxon (1949)³.

25

In control animals the CC₅₀ is usually 14 - 18 mA. Hence the first animal in the control group is subjected to a current of 16 mA. If a tonic seizure does not ensue, the current is increased for a subsequent mouse. If a tonic convulsion does occur, then the current is decreased, and so on until all the animals in the group have been tested.

30

Studies are carried out using a Hugo Sachs Elektronik Constant Current Shock Generator with totally variable control of shock level from 0 to 300 mA and steps of 2 mA are usually used.

35 Method for rat model

The threshold for maximal (tonic hindlimb extension) electroshock seizures in male rats (Sprague Dawley, 80 - 150g, 6 weeks old) was determined by a Hugo Sachs Elektronik stimulator which delivered a constant current (0.3 sec duration; from 1-300mA in steps of

5-20mA). . The procedure is similar to that outlined above for mouse and full details are as published by Upton et al.,⁴

5 The percentage increase or decrease in CC₅₀ for each group compared to the control is calculated.

Drugs are suspended in 1% methyl cellulose.

References

10


1. Loscher, W. and Schmidt, D. (1988). *Epilepsy Res.*, **2**, 145-181
2. Dixon, W.J. and Mood, A.M. (1948). *J. Amer. Stat. Assn.*, **43**, 109-126
3. Litchfield, J.T. and Wilcoxon, F.(1949). *J. Pharmacol. exp. Ther.*, **96**, 99-113
4. N.Upton, T.P.Blackburn, C.A.Campbell, D.Cooper, M.L.Evans, H.J.Herdon, P.D.King,
15 A.M.Ray, T.O.Stean, W.N.Chan, J.M.Evans and M.Thompson. (1997). *B. J. Pharmacol.*,
121, 1679-1686

Results for rat MEST

- 20 Compounds of this invention dosed by the oral route as a suspension in methyl cellulose and tested one hour post dosing show an increase in seizure threshold. For example, the product of Example 1 showed a statistically significant increase (225 %) when examined in the rat model at a dose of 2 mg/kg p.o.

CLAIMS

1, A compound of formula (I) or pharmaceutically acceptable salt thereof:



10 where P and Q are independently methylene or ethylene groups such the ring structure Z is a five or six membered ring,

R^1 is hydrogen or C_{1-6} alkyl,

R^2 is hydrogen or up to four substituents independently selected from halogen, CF_3 , NO_2 , CN , N_3 , C_{1-6} alkylo-, C_{1-6} alkyls-, C_{1-6} alkyl, C_{3-6} cycloalkyl,

15 C_{3-6} cycloalkyl- C_{1-4} alkyl-, C_{1-6} alkenyl, C_{1-6} alkynyl, CF_3CO -, CF_3O -, C_{1-6} alkylCO-, C_{3-6} cycloalkylCO-, C_{3-6} cycloalkyl- C_{1-4} alkylCO-, phenyl, phenoxy, benzyloxy, benzoyl, phenyl- C_{1-4} alkyl-, or $-NR^4R^5$ where R^4 is hydrogen or C_{1-4} alkyl, and R^5 is hydrogen, C_{1-4} alkyl, $-CHO$, $-CO_2C_{1-4}$ alkyl or $-COC_{1-4}$ alkyl, and

20 R^3 is hydrogen or up to two C_{1-6} alkyl groups.

2. A compound according to claim 1 which is a carboxylic acid (tetrahydroisoquinolin-5-yl) or (tetrahydroisoquinolin-7-yl) amide.

3. A compound according to claim 1 or 2 which is a 3,4-dihydro-1H-isoquinoline or 3,4-dihydro-2H-quinoline or 2,3-dihydroindole N-carboxamide.

4. A compound according to claim 1, 2 or 3 in which


30 R^1 is hydrogen, methyl, ethyl or propyl,

R^2 is hydrogen, or one or more of methyl, ethyl, *n*-butyl, phenyl, *iso*-propyl, *t*-butyl, methoxy, ethoxy, *n*-propoxy, *iso*-propoxy, *n*-butoxy, phenoxy, benzyloxy, bromo, chloro, fluoro, iodo, nitro, cyano, acetyl, pivaloyl, *iso*-butyryl, benzoyl, iodobenzoyl, trifluoromethyl, trifluoromethoxy, trifluoroacetyl, amino, acetylamino, methylthio, *n*-propylsulfonyl, isopropylsulfonyl or dimethylsulfamoyl, and

35


R³ is hydrogen or one or more methyl groups.

5. A compound according to claim 1 which is
2,3-dihydroindole-1-carboxylic acid (2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)amide,
5 3,4-dihydro-1H-isoquinoline-2-carboxylic acid (2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)amide,
2,3-dihydro-2H-quinoline-1-carboxylic acid (2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)amide,
2,3-dihydro-5-methylthio-6-trifluoromethyl-indole-1-carboxylic acid (2-methyl-1,2,3,4-
10 tetrahydroisoquinolin-5-yl)amide,
2,3-dihydro-6-methoxyindole-1-carboxylic acid (2-methyl-1,2,3,4-tetrahydro-
isoquinolin-7-yl)amide,
2,3-dihydro-4-methoxyindole-1-carboxylic acid (2-methyl-1,2,3,4-tetrahydro-
isoquinolin-7-yl)amide,
15 2,3-dihydro-4,5,6,7-tetrafluoroindole-1-carboxylic acid (2-methyl-1,2,3,4-
tetrahydroisoquinolin-7-yl)amide,
2,3-dihydro-5-fluoroindole-1-carboxylic acid (2-methyl-1,2,3,4-tetrahydro-
isoquinolin-7-yl)amide,
2,3-dihydro-5-nitroindole-1-carboxylic acid (2-methyl-1,2,3,4-tetrahydro-
20 isoquinolin-7-yl)amide,
2,3-dihydro-6-nitroindole-1-carboxylic acid (2-methyl-1,2,3,4-tetrahydro-
isoquinolin-7-yl)amide,
2,3-dihydro-5-methoxy-6-trifluoromethylindole-1-carboxylic acid (2-methyl-1,2,3,4-
tetrahydroisoquinolin-7-yl)amide,
25 3,3-dimethyl-2,3-dihydroindole-1-carboxylic acid (2-methyl-1,2,3,4-tetrahydro-
isoquinolin-7-yl)amide,
2,3-dimethyl-2,3-dihydroindole-1-carboxylic acid (2-methyl-1,2,3,4-tetrahydro-
isoquinolin-7-yl)amide,
2,3-dimethyl-2,3-dihydroindole-1-carboxylic acid (2-methyl-1,2,3,4-tetrahydro-
30 isoquinolin-7-yl)amide, or
3,3-dimethyl-5-fluoro-2,3-dihydroindole-1-carboxylic acid (2-methyl-1,2,3,4-
tetrahydroisoquinolin-7-yl)amide;
or a pharmaceutically acceptable salt or solvate thereof.
- 35 6. A process for the preparation of compounds of formula (I), which comprises
reacting a compound of formula (II)



where R^{1A} is R^1 as defined for formula (I) or a group convertible to R^1 ,

with a compound of formula (III)



where P, Q and Z are as defined for formula (I), and R^{2A}, R^{3A} are R^2, R^3 as defined for formula (I) or a group or groups convertible to R^2, R^3

and where required converting a R^{1A}, R^{2A} or R^{3A} group to a R^1, R^2 or R^3 group,

- 15 converting one R^1, R^2 or R^3 group to another R^1, R^2 or R^3 group, converting a salt product to the free base or another salt which is pharmaceutically acceptable, or converting a free base product to a pharmaceutically acceptable salt.

7. A pharmaceutical composition for use in the treatment and/or prophylaxis of
- 20 anxiety, mania, depression disorders associated with a subarachnoid haemorrhage or neural shock, the effects associated with withdrawal from substances of abuse such as cocaine, nicotine, alcohol and benzodiazepines, disorders treatable and/or preventable with anti-convulsive agents, such as epilepsy including post-traumatic epilepsy, Parkinson's disease, psychosis, migraine, cerebral ischaemia, Alzheimer's disease and other degenerative
- 25 diseases such as Huntingdon's chorea, schizophrenia, obsessive compulsive disorders (OCD), neurological deficits associated with AIDS, sleep disorders (including circadian rhythm disorders, insomnia & narcolepsy), tics (e.g. Gilles de la Tourette's syndrome), traumatic brain injury, tinnitus, neuralgia, especially trigeminal neuralgia, neuropathic pain, dental pain, cancer pain, inappropriate neuronal activity resulting in neurodysthesis
- 30 in diseases such as diabetes, multiple sclerosis (MS) and motor neurone disease, ataxias, muscular rigidity (spasticity), temporomandibular joint dysfunction, panic disorders and/or aggression which comprises a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier.

8. A method of treatment and/or prophylaxis of anxiety, mania, depression disorders associated with a subarachnoid haemorrhage or neural shock, the effects associated with withdrawal from substances of abuse such as cocaine, nicotine, alcohol and benzodiazepines, disorders treatable and/or preventable with anti-convulsive agents, such as epilepsy including post-traumatic epilepsy, Parkinson's disease, psychosis, migraine, cerebral ischaemia, Alzheimer's disease and other degenerative diseases such as Huntingdon's chorea, schizophrenia, obsessive compulsive disorders (OCD), neurological deficits associated with AIDS, sleep disorders (including circadian rhythm disorders, insomnia & narcolepsy), tics (e.g. Gilles de la Tourette's syndrome), traumatic brain injury, tinnitus, neuralgia, especially trigeminal neuralgia, neuropathic pain, dental pain, cancer pain, inappropriate neuronal activity resulting in neurodysthesias in diseases such as diabetes, multiple sclerosis (MS) and motor neurone disease, ataxias, muscular rigidity (spasticity), temporomandibular joint dysfunction, panic disorders and/or aggression comprising administering to the sufferer in need thereof an effective or prophylactic amount of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof.
9. Use of a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, for the manufacture of a medicament for the treatment and/or prophylaxis of anxiety, mania, depression disorders associated with a subarachnoid haemorrhage or neural shock, the effects associated with withdrawal from substances of abuse such as cocaine, nicotine, alcohol and benzodiazepines, disorders treatable and/or preventable with anti-convulsive agents, such as epilepsy including post-traumatic epilepsy, Parkinson's disease, psychosis, migraine, cerebral ischaemia, Alzheimer's disease and other degenerative diseases such as Huntingdon's chorea, schizophrenia, obsessive compulsive disorders (OCD), neurological deficits associated with AIDS, sleep disorders (including circadian rhythm disorders, insomnia & narcolepsy), tics (e.g. Gilles de la Tourette's syndrome), traumatic brain injury, tinnitus, neuralgia, especially trigeminal neuralgia, neuropathic pain, dental pain, cancer pain, inappropriate neuronal activity resulting in neurodysthesias in diseases such as diabetes, multiple sclerosis (MS) and motor neurone disease, ataxias, muscular rigidity (spasticity), temporomandibular joint dysfunction, panic disorders and/or aggression.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 98/07520

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07D401/12 C07D217/06 A61K31/47

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 96 39382 A (FUJISAWA PHARMACEUTICAL CO., LTD) 12 December 1996 cited in the application see claims	1-9
A	WO 93 18028 A (SMITHKLINE BEECHAM PLC) 16 September 1993 see claims	1-9
A	WO 94 04533 A (SMITHKLINE BEECHAM PLC) 3 March 1994 see claims	1-9
A	WO 94 22871 A (SMITHKLINE BEECHAM PLC) 13 October 1994 see claims	1-9

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

5 March 1999

Date of mailing of the international search report

15/03/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Henry, J

INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP 98/07520

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 8
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claim 8
is directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 98/07520

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9639382	A	12-12-1996	NONE	
WO 9318028	A	16-09-1993	EP 0630373 A	28-12-1994
			JP 7504429 T	18-05-1995
			MX 9301336 A	01-10-1993
			US 5508288 A	16-04-1996
			ZA 9301713 A	22-09-1994
WO 9404533	A	03-03-1994	AU 4704693 A	15-03-1994
			CA 2142721 A	03-03-1994
			CN 1086819 A	18-05-1994
			EP 0656003 A	07-06-1995
			JP 8500580 T	23-01-1996
			MX 9305037 A	31-03-1994
			NZ 254785 A	26-09-1995
			SI 9300438 A	31-03-1994
			ZA 9306050 A	20-02-1995
WO 9422871	A	13-10-1994	EP 0691973 A	17-01-1996
			JP 8508275 T	03-09-1996